सेफ्टाज़िडिम के इंटरैक्शन

हम जिन FDA लेबल और फैक्ट शीट को इंडेक्स करते हैं, उनमें सेफ्टाज़िडिम (Fortaz, Tazicef; सेफालोस्पोरिन) के 118 इंटरैक्शन दर्ज हैं: 17 गंभीर, 48 मध्यम, 53 मामूली, और 0 ऐसे जिनमें लेबल बताता है कि कोई महत्वपूर्ण इंटरैक्शन नहीं है। नीचे की हर प्रविष्टि उस वाक्य को उद्धृत करती है जिस पर वह आधारित है। दवा का यह पेज एक शुरुआती बिंदु है, आपकी स्थिति के लिए कोई फ़ैसला नहीं।

लेबल से लिए गए इंटरैक्शन

गंभीर इंटरैक्शन (17)

  • इमिपेनेम और सिलास्टैटिनएंटीबायोटिकगंभीर

    Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. (इमिपेनेम और सिलास्टैटिन लेबल, चेतावनियां और सावधानियां)

  • एमोक्सिसिलिनपेनिसिलिन एंटीबायोटिकगंभीर

    AMOXIL is contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to AMOXIL or to other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins). (एमोक्सिसिलिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एमोक्सिसिलिन और क्लैवुलैनेटपेनिसिलिन एंटीबायोटिकगंभीर

    History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to AUGMENTIN or to other beta‑lactams (e.g., penicillins or cephalosporins). (एमोक्सिसिलिन और क्लैवुलैनेट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एम्पीसिलिनपेनिसिलिन एंटीबायोटिकगंभीर

    CONTRAINDICATIONS The use of Ampicillin is contraindicated in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to ampicillin or to other beta-lactam antibacterial drugs. (एम्पीसिलिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एम्पीसिलिन और सल्बैक्टमपेनिसिलिन एंटीबायोटिकगंभीर

    CONTRAINDICATIONS The use of UNASYN is contraindicated in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to ampicillin, sulbactam or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins). (एम्पीसिलिन और सल्बैक्टम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एर्टापेनेमएंटीबायोटिकगंभीर

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • नैफसिलिनपेनिसिलिन एंटीबायोटिकगंभीर

    WARNINGS Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs. (नैफसिलिन लेबल, चेतावनियां)

  • पाइपेरासिलिन और टैज़ोबैक्टमपेनिसिलिन एंटीबायोटिकगंभीर

    Piperacillin and Tazobactam for Injection and Sodium Chloride Injection is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or betalactamase inhibitors. (पाइपेरासिलिन और टैज़ोबैक्टम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफाक्लोरसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफाज़ोलिनसेफालोस्पोरिनगंभीर

    Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (सेफाज़ोलिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफिक्सिमसेफालोस्पोरिनगंभीर

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (सेफिक्सिम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफेपिमसेफालोस्पोरिनगंभीर

    Patients with known immediate hypersensitivity reactions to cefepime or other cephalosporins, penicillins or other beta-lactam antibacterial drugs. (सेफेपिम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफैलेक्सिनसेफालोस्पोरिनगंभीर

    Cephalexin is contraindicated in patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugs. (सेफैलेक्सिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफॉक्सिटिनसेफालोस्पोरिनगंभीर

    Hypersensitivity to cefoxitin or other beta-lactam antibacterial drugs. (सेफॉक्सिटिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफ्टारोलिनसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Teflaro is contraindicated in patients with known serious hypersensitivity to ceftaroline or other members of the cephalosporin class. (सेफ्टारोलिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफ्ट्रिएक्सोनसेफालोस्पोरिनगंभीर

    Anaphylaxis to ceftriaxone or other cephalosporin class antibacterials, penicillins, or other beta-lactam antibacterials ( 4.1 ) (सेफ्ट्रिएक्सोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफ्यूरोक्सिमसेफालोस्पोरिनगंभीर

    Known hypersensitivity (e.g., anaphylaxis) to cefuroxime axetil or to other β-lactams (e.g., penicillins and cephalosporins). (सेफ्यूरोक्सिम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

मध्यम इंटरैक्शन (48)

  • इंडापामाइडथायज़ाइड डाइयूरेटिकमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • इर्बेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • एज़ट्रियोनमएंटीबायोटिकमध्यम

    Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (एज़ट्रियोनम लेबल, चेतावनियां और सावधानियां)

  • एटेनोलोल और क्लोरथैलिडोनबीटा ब्लॉकरमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • एथाक्रिनिक एसिडलूप डाइयूरेटिकमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • एप्लेरेनोनएल्डोस्टेरोन एंटागोनिस्टमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • एमिकासिनएमिनोग्लाइकोसाइडमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • एमिलोराइडपोटैशियम-स्पेयरिंग डाइयूरेटिकमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • एसिटाज़ोलामाइडकार्बोनिक एनहाइड्रेज़ इनहिबिटरमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • ऑक्सासिलिनपेनिसिलिन एंटीबायोटिकमध्यम

    IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS- HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBACTERIAL DRUGS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • ओल्मेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • ओल्मेसार्टन, एम्लोडिपिन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • कैंडेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • क्लोरथैलिडोनथायज़ाइड डाइयूरेटिकमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • क्लोरोथायज़ाइडथायज़ाइड डाइयूरेटिकमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • जेंटामाइसिनएमिनोग्लाइकोसाइडमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • टेल्मिसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • टॉरसेमाइडलूप डाइयूरेटिकमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • टोब्रामाइसिनएमिनोग्लाइकोसाइडमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • ट्रायमटेरिनपोटैशियम-स्पेयरिंग डाइयूरेटिकमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • ट्रायमटेरिन और हाइड्रोक्लोरोथायज़ाइडपोटैशियम-स्पेयरिंग डाइयूरेटिकमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • डाइक्लोक्सासिलिनपेनिसिलिन एंटीबायोटिकमध्यम

    IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS- HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBACTERIAL DRUGS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • नियोमाइसिनएमिनोग्लाइकोसाइडमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • पेनिसिलिन Gपेनिसिलिन एंटीबायोटिकमध्यम

    IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS- HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBACTERIAL DRUGS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • पेनिसिलिन Vपेनिसिलिन एंटीबायोटिकमध्यम

    IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS- HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBACTERIAL DRUGS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • Drug Interactions Protamine sulfate has been shown to be incompatible with certain antibiotics, including several of the cephalosporins and penicillins (see DOSAGE AND ADMINISTRATION ). (प्रोटामिन लेबल, सावधानियां)

  • Drug Interactions When probenecid is used to elevate plasma concentrations of penicillin or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (प्रोबेनेसिड लेबल, दवाओं के इंटरैक्शन)

  • DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (प्रोबेनेसिड और कोल्चिसिन लेबल, दवाओं के इंटरैक्शन)

  • प्लाज़ोमाइसिनएमिनोग्लाइकोसाइडमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • फ्यूरोसेमाइडलूप डाइयूरेटिकमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • बुमेटेनाइडलूप डाइयूरेटिकमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • माइकोफेनोलेटइम्यूनोसप्रेसेंटमध्यम

    Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate… (माइकोफेनोलेट लेबल, दवाओं के इंटरैक्शन)

  • Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • मेटोलाज़ोनथायज़ाइड डाइयूरेटिकमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • लोसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • वाल्सार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • सेफपोडोक्सिमसेफालोस्पोरिनमध्यम

    Probenecid As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • सेफोटेटनसेफालोस्पोरिनमध्यम

    THERE APPEARS TO BE AN INCREASED RISK OF DEVELOPING HEMOLYTIC ANEMIA ON CEFOTETAN RELATIVE TO OTHER CEPHALOSPORINS OF AT LEAST 3 FOLD. (सेफोटेटन लेबल, चेतावनियां)

  • सेफोटैक्सिमसेफालोस्पोरिनमध्यम

    Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (सेफोटैक्सिम लेबल, दवाओं के इंटरैक्शन)

  • स्पिरोनोलैक्टोनएल्डोस्टेरोन एंटागोनिस्टमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • स्पिरोनोलैक्टोन और हाइड्रोक्लोरोथायज़ाइडएल्डोस्टेरोन एंटागोनिस्टमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • हाइड्रोक्लोरोथायज़ाइडथायज़ाइड डाइयूरेटिकमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

मामूली ज़िक्र (53)

  • आर्टिकेन और एड्रेनालिनलोकल एनेस्थेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • एज़ेलास्टिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • एज़ेलास्टिन और फ्लुटिकासोनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • एड्रेनालिनसिम्पैथोमिमेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • ओलोपाटाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • ओलोपाटाडीन और मोमेटासोनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • कार्बिनोक्सामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • क्लेमास्टिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • क्लोबेटासोलकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • क्लोरफेनिरामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • ट्रायमसिनोलोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • डाइफेनहाइड्रामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • डाइमेनहाइड्रिनेटएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • डेक्सक्लोरफेनिरामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • डेक्सामेथासोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • डेफ्लाज़ाकॉर्टकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • डेसलोराटाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • डेसोनाइडकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • डॉक्सीलामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • डॉक्सीलामिन और पाइरिडोक्सिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • प्रिलोकेन और एड्रेनालिनलोकल एनेस्थेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • प्रेडनिसोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • प्रेडनिसोलोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • प्रोमेथाज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • फेक्सोफेनाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • फ्लुओसिनोनाइडकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • फ्लुटिकासोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • फ्लुटिकासोन और सैल्मेटेरोलकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • फ्लुड्रोकॉर्टिसोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • फ्लुनिसोलाइडकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • बीटामेथासोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • बुडेसोनाइडकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • बुडेसोनाइड और फॉर्मोटेरोलकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • बेक्लोमेथासोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • ब्यूपिवाकेन और एड्रेनालिनलोकल एनेस्थेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • मिथाइलप्रेडनिसोलोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • मेक्लिज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • मेरोपेनेमएंटीबायोटिकमामूली

    Before initiating therapy with Meropenem for injection, it is important to inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams, and other allergens. (मेरोपेनेम लेबल, चेतावनियां और सावधानियां)

  • मोमेटासोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • लिडोकेन और एड्रेनालिनलोकल एनेस्थेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • लेवोसेटिरिज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • लोराटाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • साइप्रोहेप्टाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • सिक्लेसोनाइडकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • सेटिरिज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • सेफडिनिरसेफालोस्पोरिनमामूली

    WARNINGS BEFORE THERAPY WITH CEFDINIR IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFDINIR, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. (सेफडिनिर लेबल, चेतावनियां)

  • हाइड्रॉक्सीज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • हाइड्रोकॉर्टिसोनकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

  • हेलोबेटासोलकॉर्टिकोस्टेरॉइडमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफ्टाज़िडिम लेबल, चेतावनियां)

आप जो कुछ भी लेते हैं, उस सबके साथ सेफ्टाज़िडिम को जांचें। अपनी पूरी सूची जोड़ें; हर जोड़ी एक साथ जांची जाती है।

चेकर में खोलें

यह चिकित्सकीय सलाह नहीं है। गंभीरता लेबल के शब्दों को दर्शाती है, आपकी परिस्थितियों को नहीं। “गंभीर” चिह्न वाला संयोजन डॉक्टर की देखरेख में सामान्य बात हो सकता है, और “मामूली” चिह्न वाला संयोजन ऊंची खुराक पर मायने रख सकता है। फार्मासिस्ट से पूछें।